Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Pacer Advisors Inc. lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 98.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 9,251 shares of the company’s stock after selling 484,736 shares during the quarter. Pacer Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $279,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in TEVA. Global Retirement Partners LLC increased its position in Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. Captrust Financial Advisors boosted its holdings in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after acquiring an additional 302 shares in the last quarter. Banque Cantonale Vaudoise boosted its holdings in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after acquiring an additional 306 shares in the last quarter. Ethic Inc. grew its stake in Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after acquiring an additional 325 shares during the period. Finally, Allworth Financial LP grew its stake in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Activity

In other news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 259,831 shares of company stock valued at $9,091,659. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.9%

Shares of NYSE:TEVA opened at $36.48 on Wednesday. The business’s 50 day moving average is $33.35 and its 200 day moving average is $32.89. Teva Pharmaceutical Industries Ltd. has a 12-month low of $16.26 and a 12-month high of $37.35. The stock has a market cap of $42.51 billion, a price-to-earnings ratio of 60.79, a PEG ratio of 3.87 and a beta of 0.86. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The business had revenue of $4.14 billion during the quarter. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Finally, Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.